FDA seeks evidence from another study of motavizumab

08/30/2010 | Wall Street Journal, The

MedImmune received a second complete-response letter from the FDA for motavizumab, an experimental drug to prevent serious respiratory syncytial virus. The agency asked for clinical data from an additional study that supports a "satisfactory risk/benefit profile in the population for which the prophylaxis indication is being requested."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL